Emerging retatrutide, a combined-action medication targeting both GLP-1 and GIP receptors, is creating considerable excitement within the weight loss community. Preliminary clinical studies have shown substantial losses in body weight and gains in physiological markers for people with overweight. Researchers believe this ground-breaking approach co